Louis Lange
Partner @ Asset Management Ventures (AMV)
Palo Alto, United States
Louis Lange is a seed investor at Asset Management Ventures (AMV) in Palo Alto focused on Health Care and Biotechnology. Louis Lange - Partner @ Asset Management Ventures (AMV)
- Total investments:
- 18
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Louis Lange invests in
Stages Louis Lange invests in
Countries Louis Lange invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 10 (56%)
- Biotechnology 9 (50%)
- Medical 5 (28%)
- Genetics 3 (17%)
- Pharmaceutical 3 (17%)
Stage
- Seed 5 (28%)
- Funding Round 3 (17%)
- Series A 2 (11%)
- Series B 2 (11%)
- Convertible Note 2 (11%)
Country
- United States 10 (56%)
- Ireland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California. | $6M / Seed / Sep 18, 2019 | ||
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | Convertible Note / Sep 17, 2019 | |
|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | Convertible Note / Nov 28, 2017 | |
| Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California. | $12M / Seed / Oct 04, 2017 | ||
| Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists topermanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses.The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors. | $11.5M / Series A / Jun 29, 2017 | ||
| Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving andrelapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies.Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders. | Seed / May 19, 2017 | ||
| Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California. | Convertible Note / Feb 28, 2017 | ||
|
Aegis Surgical
|
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis. | $5.6M / Series B / Jan 04, 2016 | |
| Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is basedin Cupertino, California. | $13.2M / Series B / Dec 16, 2015 | ||
| Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients. | $65M / Series C / Oct 13, 2015 | ||
| See all 18 investments → | |||
Co-Investors
AMV is a venture capital firm investing in early-stage digital health, tech, and life sciences companies.
Asset Management Ventures (AMV) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rich Simoni
Managing Partner
|
|||
Skip Fleshman
Partner
|
|||
|
Louis Lange
Partner
|
|||
|
Pitch Johnson
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Louis Lange invest in?
Louis Lange invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Louis Lange?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Louis Lange last invest?
The most recent investment recorded for Louis Lange closed in Sep 2019. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
